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Abstract
COPD is the 4th leading cause of death in the United States and is the leading cause of
hospitalizations in adults.1 Although there is no cure for COPD, symptoms can be managed to
increase the quality of life of those affected by the disease. Dietary omega-3 and -6 as well as
fiber intakes have been noted as mitigating the burden of disease through their anti-inflammatory
properties. We set out to look at the synergistic effect of both omega-3,-6, -6:-3 ratio and fiber on
COPD, lung function and respiratory morbidities. We used data from the National Heath and
Nutritional Examination Survey (NHANES) to examine the relationship of COPD lung function
outcomes (COPD yes/no, COPD GOLD classification, and FEV 1/FVC score) and symptoms
with omega-3, -6, omega 6:3 ratio and fiber intakes. We found that dietary fiber intake was
associated with COPD status (p=0.0381), cough (p=0.0109), and chronic bronchitis (p=0.0392).
We found no significant associations between omega-3 intake and COPD and respiratory
outcomes or between omega-6 intake and COPD and respiratory outcomes. We did observe an
interaction of fiber quartiles and omega 6 (p=0.0269) and omega 6:3 (p=0.0142) on COPD
status. Future studies should examine this interaction further.

Chapter 1- Introduction & Background
COPD
COPD affects 1 in 8 Americans age 45 and older and is the 4th leading cause of death in
the US.1 Currently there are 16 million people diagnosed with COPD, and likely others have the
disease, but have not been diagnosed.2 COPD is also a leading cause of hospitalization in US
adults, particularly in older populations,3 and it is estimated that the cost of COPD patient-related
care in 2020 will be $49 billion.1

The Global Initiative for Chronic Obstructive Lung Disease describes COPD as, “a
disease state characterized by airflow limitation that is not fully reversible. The airflow limitation
is usually both progressive and associated with an abnormal inflammatory response of the lungs
to noxious particles or gases”.4 One of the main risk factors for COPD is smoking. Also
included are air pollution, asthma, occupational exposures, airway hyperresponsiveness, and
specific germline genetic variations.2
While there is no cure for COPD, disease symptoms can be managed to improve quality
of life. An American Lung Association survey stated that half (51%) of all COPD patients say
their condition limits their ability to work. The condition also limits COPD patients in normal
physical exertion (70%), household chores (56%), social activities (53%), sleeping (50%), and
family activities (46%).5 Pharmacologic treatments do not improve damage to the lung, but can
slow lung function decline.2
Recent studies have shown that factors that down-regulate inflammatory activity might
be particularly useful in diseases characterized by continuous inflammation, like COPD.6 Many
chronic conditions, such as cancer, obesity, autoimmune diseases, rheumatoid arthritis, asthma
and depression, are associated with increased production of inflammatory mediator including
thromboxane A2 (TXA2), leukotriene B4 (LTB4), IL-1β, IL-6, tumor necrosis factor-alpha (TNFα), and C-reactive protein (CRP). It has been shown that all these inflammatory factors increase
with omega-6 fatty acid intake and decrease with omega-3 fatty acid intake.7

Dietary Omega -3 and -6
Dietary intake of omega-3 and omega-6 fatty acids, also known as n-3 and n-6
polyunsaturated fatty acids (PUFA), have been shown to be associated with serum inflammatory

markers.8 A diet rich in omega-6 fatty acids shifts the physiological state to one that is
proinflammatory.9 Many studies have provided evidence that incorporation of alternative fatty
acids may modify inflammatory and immune reactions and that omega-3 fatty acids in particular
are potent therapeutic agents for inflammatory diseases.7
Previous studies have shown an inverse association between the n-3 fatty acid alphalinolenic acid (ALA) intake and several proinflammatory biomarkers, including CRP, IL-6 and
TNF-α. 8 This was seen in both healthy populations and among subjects with cardiovascular
disease. In contrast, intake of omega-6 fatty acids, specifically arachidonic acid (ARA), were
associated with proinflammatory molecules IL-6 and CRP.8 Shahar et al. reported a dosedependent decrease in risk of chronic obstructive pulmonary disease with increasing intake of
n−3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).10 They also
stated that even though most of the anti-inflammatory effects of n-3 fatty acids were
demonstrated using dietary supplements that provide doses much higher than the average intake,
very small increases in intake may have health benefits, showing potential of a cumulative
effect.10 An additional study showed that inclusion of omega−3 fatty acids in the diet can
suppress the production of both TNF-α and IL-1β, two proinflammatory cytokines.11
Pizzini and colleagues demonstrated the anti-inflammatory proprieties of omega-3 in
sixty-four COPD patients receiving either an omega-3 (alpha-linolenic acid (ALA)) or an omega6 (linoleic acid (LA)) fatty acid supplementation diet for two years.12 In addition to various
clinical improvements, patients consuming the omega-3 rich diet showed significant decrease in
proinflammatory molecules, specifically, leukotriene B4 levels in serum and sputum, as well as
TNFα and IL-8 levels in sputum.12

There is also growing evidence that the omega 3 fatty acid docosapentaenoic acid (DPA)
may have both independent and shared health outcomes with EPA and DHA and may be
important when considering total dietary omega 3 intake.13
On the other hand, there are some studies that highlight the conflicting evidence
supporting the association between omega-3, omega-6 and COPD.24 They noted the variation in
methodology for the limited available studies and the need for further investigation, because
some studies report no association, some report a negative association, and some report a
positive association.

Fiber
Studies have also examined the role of fiber in diseases characterized by chronic
inflammation. The beneficial association of dietary fiber with lung function and COPD has been
attributed to the anti-inflammatory and/or antioxidant properties of fiber.14 Fiber intake has been
associated with reduced levels of CRP, a marker of systemic inflammation. Other mechanisms in
which fiber may modulate inflammation include slowing the absorption of glucose, decreasing
lipid oxidation, or influencing the production of anti-inflammatory cytokines by the gut flora.14
Kan et al. found a statistically significant dose-response relationship between lung function
(FEV1, FVC, FEV1/FVC ratio) and dietary fiber from all sources, in both basic and adjusted
models.14 Statistically significant associations between total fiber intake and FEV1 were
observed in all subgroups, with little evidence of interaction.14
In a prospective study, Varraso et al. examined two large cohorts of US women and men,
where they found that participants with a higher total fiber intake had a lower risk of incident
COPD, even after adjustment for potential confounders.15 They also reported a significant and

independent association between total fiber intake and the risk of COPD, particularly in
women.15
A systematic review and meta-analysis by Sevedrezazadeh et al. reported that
longitudinal studies have supported the inverse association between fiber intake and COPD,
which was related to anti-inflammatory properties of dietary fiber. Their analysis found that fiber
intake was associated with lower levels of CRP and pro-inflammatory cytokines and higher
levels of several anti-inflammatory cytokines.16 They also stated that fiber intake reduced the risk
of COPD, chronic bronchitis, and emphysema, and COPD symptoms according to cohort
studies.16
A study examining 10-year trends in fiber intake reported that mean intakes of fiber from
the 2001-2010 NHANES population were well below the current recommendations for all age
groups.17 Their analysis also showed no increase in fiber intake in adults ages 19 to 50 years, and
a 0.8g/day increase for adults ages 51+.

Aims
To date, no studies have looked at the synergistic effect of both omega-3,-6, -6:-3 ratio
and fiber on COPD, lung function and respiratory morbidities. We hope to shed light on the
function of these dietary components in COPD and their possible therapeutic effect to reduce the
burden and/or symptoms of COPD. In addition, this study seeks to determine whether the
relationship between the omega-6/omega-3 ratio, COPD, and COPD respiratory symptoms is
modified by fiber intake. We anticipate that a low dietary omega-6:3 ratio and increased fiber
intake are associated with a lower prevalence of COPD compared to those with a high omega6/omega-3 ratio and fiber intake.

Chapter 2- Methods
Study population
The study population was U.S. adults ≥40 years of age enrolled in the National Health
and Nutritional Examination Study (NHANES) from 2007 to 2012. NHANES is a crosssectional survey that targets the U.S. noninstitutionalized population of all ages and is designed
to assess health and nutrition through interviews and physical examinations. Sampling involves
a complex, multistage, clustered design and is conducted by the National Center for Health
Statistics (NCHS). Participants aged 40 years and older were included in the analysis if they had
complete data for all lung function and nutrient variables (Figure 1). Pregnant women, those
with improbable values for dietary variables, those missing BMI, smoking status, and poverty
data were excluded. Participants with asthma were excluded as well.

COPD and respiratory outcomes
COPD was treated as a dichotomous variable. A participant was considered to have
COPD if they had a pre bronchodilator forced expiratory volume in one second (FEV1)/forced
vital capacity (FVC) ratio<0.70, do not have an asthma diagnosis, and have smoked 100 or more
cigarettes in their lifetime. To examine the severity of COPD, we used % predicted FEV1. To
grade COPD airflow limitation severity, we used the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) classification based on FEV1 scores. GOLD 1 represents mild COPD
(FEV1≥ 80% predicted), GOLD 2 represents moderate (50% ≤FEV1<80% predicted), GOLD 3 is
severe (30% ≤FEV1< 50% predicted), and GOLD 4 is very severe (FEV1<30% predicted).

To examine respiratory symptoms, examined wheeze, cough, phlegm and chronic
bronchitis. Participants were asked if they had experienced wheezing or whistling in their chest
in the past 12 months. For cough, participants were asked if they usually cough on most days for
three consecutive months or more during the year. Finally, participants were asked if they bring
up phlegm on most days for three consecutive months or more during the year. A participant was
considered to have chronic bronchitis if they have both chronic cough and chronic phlegm. For
these variables, responses were recorded as a yes or no. Respiratory symptom outcomes were
used in addition to lung function outcomes to examine both the quality and quantity of lung
function.

Dietary intake of omega-3/omega-6 and fiber
Using the NHANES 24-hour dietary interview (What We Eat in America), the types and
amounts of foods and beverages consumed during the 24 hours prior to the interview were
estimated, as well as energy, nutrient and other components of those foods. The questionnaire
was used twice during NHANES data collection, the first in-person and the second 3 to 10 days
later over the telephone. From that, total nutrient intakes were calculated. We used the average
of the data for day one and two. For this study, to determine the total omega-3 intake we used
values for docosahexaenoic acid (22:6, Docosahexaenoic acid (DHA)), eicosapentaenoic acid
(20:5, Eicosapentaenoic acid (EPA)), octadecatetraenoic acid (18:4, Stearidonic acid, SDA),
docosapentanoic acid (22:5, Docosapentaenoic acid (DPA)), and octadecatrienoic acid (18:3,
Alpha-linolenic acid (ALA)). To determine the total omega-6 intake we used values for
octadecadienoic acid (18:2, Linolenic acid (LA)) and eicosatetraenoic acid (20:4, Arachidonic
acid (AA)). We chose to use these omega-3 and -6 isomers based on their categorization in

previous published research.18,19 Fiber intakes were also be assed using nutrient intake data. We
computed the ratio for omega 6:3. Fiber and omegas were examined using quartiles (Q1 low, Q2,
Q3, Q4 high).

Additional Covariates
Age was measured in years. Sex was grouped by male and female. Height and weight
were used to calculate BMI. BMI below 18.5 was considered underweight, 18.5-24.9 is normal
or healthy weight, 25.0-29.9 is overweight, and 30.0 and above is considered obese. Race was
split into four categories, non-Hispanic white, non-Hispanic black, Mexican American and other
Hispanic and other race including multi-racial. Smoking status was assessed by asking
participants about their smoking habits. Participants were asked how many cigarettes they
smoked in their entire life and if they now smoke cigarettes. This was categorized as current
smoker, former smoker, or never smoker. The poverty ratio is a ratio of family income to
poverty levels commonly used to establish eligibility for U.S. food assistance programs and was
used to adjust for socioeconomic status. Education level was assessed using respondent’s
highest level of education.

Statistical Analysis
All statistical analyses were done using SAS 9.4. Descriptive statistics and univariate
analysis were done to show distribution and summarize the data for our variables including age,
sex, BMI, race, poverty ratio, education, smoking status, wheeze, phlegm, cough, bronchitis,
FEV1/FVC, % predicted FEV1, % predicted FVC, fiber, omega-3, omega-6, and omega-6:3.

They were also stratified by COPD status. Analyses included mean, median, and standard error
of the mean. The complex survey design of NHANES was accounted for during our analysis.
Multivariable logistic regression was used to look at the association of lung function
variables (COPD yes/no, COPD GOLD classification) as well as respiratory symptoms (wheeze,
cough, chronic bronchitis and phlegm) and omega-3, -6, omega 6:3 ratio and fiber intake levels
using PROC SURVEYLOGISTIC. Linear regression was used to examine the relationship
between the lung function continuous variables FEV1/FVC ratio, % predicted FEV1, and %
predicted FVC and all dietary variables.
Multivariable regression models were adjusted for the covariates BMI (underweight
<18.5, normal 18.5-24.9, and overweight/obese 25+), poverty ratio category(≤1.9, 2-4.9, 5+), sex
(male, female), age category (40-49 years, 50-59 years, 60-69 years, and 70-19 years), race
category (Non-Hispanic white, non-Hispanic black, Mexican American and other Hispanic, and
other race, including multiracial), mean energy intake (calories/day), and smoking status (current
smoker, former smoker, never smoker). These covariates were chosen based on their biological
relevancy and based on previous research.
We also explored any possible interactions between fiber and omega quartiles and each
covariate in the models for each COPD and respiratory outcome.

Chapter 3- Results
After implementing eligibility criteria and accounting for missing data, 6938 participants
were included in the analysis (Figure 1). The study population had a mean age of 55.7 years and
consisted of 47.9% males and 52.1% females (Table 1). The majority of the study population
was Non-Hispanic White (75.4%), with a mean poverty income ratio of 3.3±0.05. The average

BMI was 29.2kg/m2. About half (51.9%) of the population reported being a high school
grad/GED and having some college or an AA degree. Most of the population were nonsmokers
(82%). Those with COPD tended to be male (60.6%), Non-Hispanic white (82.2%), and
overweight/obese (66%). They were also older, less educated, in a lower SES group as indicted
by the poverty income ratio, and more likely to be current or former smokers. Those with COPD
also tended to have higher prevalence of respiratory symptoms wheeze (20.4%), chronic phlegm
(17.9%), chronic cough (20.5%), and chronic bronchitis (13.7%) (Table 2). As expected, they
also had a lower lung function measured by FEV1/FVC and % predicted FEV1.
The mean dietary fiber intake was 17.8 g/day. High dietary fiber intake was seen in those
without COPD (Table 3). Mean omega-3 intake was 1.82 g/day and mean omega-6 intake was
16.42 g/day. The average omega 6:3 ratio was 9.69. Those with COPD had a slightly higher
mean Omega-6 (17.25g/day (±0.54)) intake compared to those without COPD (16.30g/day
(±0.18)) (p<0.0001).
Multivariable analysis revealed associations between fiber intake and COPD status
(p=0.038), cough (p=0.011), and chronic bronchitis (p=0.039) (Table 4). We found increased
odds of COPD with low fiber intake (OR=1.3; 95% CI 0.9-1.7; p=0.010), but no liner trend was
observed (p=0.08). Lower odds of cough was seen with low fiber intake (OR=0.6; 95% CI 0.40.8; p=0.001) and a liner trend was observed (p=0.003). The same association was seen between
fiber and bronchitis, lower odds of bronchitis with low fiber intakes (OR=0.6; 95% CI 0.4-1.0;
p=0.005) and a liner trend was observed (p=0.044).
No significant associations were observed between omega-3 intake and COPD and
respiratory outcomes or between omega-6 intake and COPD and respiratory outcomes. Overall,
a higher omega 6:3 ratio was associated with cough (p=0.015). An association was also

observed between fiber intake and % predicted FEV1 (p=0.0001) as well as fiber intake and %
predicted FVC (p<0.0001) (Table 5).
Tests for interaction revealed significant interactions of fiber quartiles with omega 6
(high/low) (p=0.027) and omega 6:3 (high/low) (p=0.014) in predicting COPD status. There was
also significant interaction between for fiber quartiles and omega 3 (high/low) in predicting
bronchitis (p=0.037) and wheeze (p=0.013). We found that the effect of fiber on COPD outcome
depends on the amount of omega-6 and omega-6:3. When omega-6 was low, the odds of having
COPD were increased across all levels of fiber (Table 6). Meanwhile, the odds of COPD were
lower when omega-6 intake was high across all levels of fiber. The same trend was seen with
omega-6:3, when omega-6:3 was low, the odds of having COPD were increased and in the group
with high omega-6:3, the odds of COPD were lower.

Chapter 4- Discussion
The goal of this study was to examine the relationship of fiber, omega-3 and omega-6
intake with COPD and respiratory outcomes in the U.S. adult (>40 years) NHANES population.
The results support our hypothesis that lower fiber intake is associated with higher odds of
COPD. We found the inverse to be true for chronic cough and chronic bronchitis, lower odds of
these two respiratory symptoms with low fiber intake. Concurrent with these observations, lung
function as measured by % predicted FEV1 and FVC was positively correlated with fiber intake.
In contrast, intake of omega -3 or -6 and the omega-6:omega-3 ratio was not associated with
COPD or any of the respiratory symptoms tested. We also found increased odds of COPD across
all levels of fiber when omega-6 intake was low and when omega-6:3 ratio is low, which is the
first observation of this interaction.

Data from our study support the protective role of a high-fiber diet against COPD.
Consumption of a high-fiber diet was associated with lower odds of COPD. A linear pattern for
wheeze, cough, phlegm, and chronic bronchitis was found, suggesting dietary fiber consumption
also plays a protective role in respiratory outcomes. Fiber was also found to be positively
associated with lung function as measured by % predicted FEV1 and FVC. These findings are
consistent with previous reports.
One study examining men and women with COPD in the US and adjusting for the same
covariates found a negative association between total dietary fiber intake and risk of newly
diagnosed COPD.15 A study that followed Sweedish men for an average of 13 years found a
negative association between total fiber intake and incident COPD in current and ex-smokers.26
A 2019 systematic review and meta-analysis also reported a negative association between fiber
consumption and risk of COPD.16 Additionally, a study using the NHANES 2009-2010
population found that high fiber intake was associated with normal lung function as measured by
% predicted FEV1 and FVC, which is consistent with the results from our study.20 They also
found no association between dietary fiber intake and COPD severity based on the GOLD scale
was found, which is also consistent with our results.20
In the current study, the protective effects of omega-3 on COPD and respiratory
symptoms were not observed. Another study using the NHANES 2007-2012 population also
found lack of association between omega-3 intake (DHA+EPA+ALA) and respiratory
symptoms.21 A review by Pinizzi and colleagues concluded the evidence showed weak benefits
of omega-3 consumption on reducing the risk of COPD.12 On the other hand, many previous
studies reported a protective role of dietary omega-3 intake on COPD and respiratory
morbidities. One study by Lemoine et al. reported a positive association between omega-3 intake

and COPD.23 They used a different summation of total omega intake different from our study
(EPA+DHA+ALA) that was reported from a food frequency questionnaire in a population of
adults in Maryland.23 Another study examining 250 clinically stable COPD patients using two
years of dietary data to measure DHA, EPA, and ALA intake reported lower levels of serum
inflammatory markers in individuals with high ALA intake.8 Also, a study enrolling current or
former smokers found that increased DHA and EPA consumption was associated with lower risk
of COPD.10 The anti-inflammatory mechanism of the omega-3s EPA, DHA , and ALA are well
researched, but there is not as much information regarding the other omega-3s considered in our
study (SDA and DPA), presenting a potential limitation.
Overall, our population with COPD had a higher mean omega-6 intake, but no significant
associations were found with any of the outcomes. Previous studies note a potential adverse
association between omega-6 intake and COPD and respiratory outcomes using the same total
omega-6 intake measure we used (LA+AA). Batlle et al. found lower serum inflammatory
markers in COPD patients with higher omega-3 intake and higher inflammatory markers in those
with higher omega-6 intake, supporting the proposed mechanisms.8 A systematic review by
Scoditti et al. assessed diet quality and COPD and lung function outcomes.25. They concluded
that an overall high-quality diet was more important than individual nutrients when considering
lung function and COPD outcomes. A study using a total omega-6 intake of LA and AA in 250
clinical COPD patients noted that higher AA intake was associated with higher levels of serum
inflammatory markers.8 The study by Lemoine et al. found omega-6 intake (LA+AA) to be
associated with lower lung function, measured by % predicted FEV1.23 The same study also
described an adverse association between the omega-6/omega-3 ratio and respiratory symptoms

in those with COPD. In our study, total omega-6/omega-3 was associated with cough, but
otherwise, our results do not indicate an association with the ratio and the other outcomes.
Few studies have examined the omega-6/omega-3 ratio. One review noted the
importance of a lower omega-6/omega-3 ratio to reduce the risk of many chronic inflammatory
diseases, although COPD was not considered.28 Many of the studies examining these omega-3
and omega-6 relationships used smaller populations and different dietary assessments as well as
different outcome measurements. Although we used the same measure of omega-6, we included
two additional components (SDA and DPA) in our omega-3 summation. These differing aspects
of the studies could be responsible for the difference in findings and determining the optimal
calculation would be beneficial for future research.
Systematic reviews conducted in 2015 and 2019 both noted the conflicting evidence and
methodological variation in previous studies examining the omega-3, omega-6 and COPD
relationship.24,25 Some studies report benefits of increased omega-3 intake on COPD and no
effect with omega-6, while others report a negative association between omega-6 consumption
and no effect of omega-3 on COPD.25 The differences in findings illustrate the complexity of
using diet as an exposure. We must consider how total dietary intakes are determined when
interpreting the results as well as how the populations are selected and what other dietary
variables are considered and accounted for.
Although some studies have examined the interactive effects of omega-3 and omega-6,
interactions between omega-3, omega-6, and fiber intake have not yet been explored until now.
In this study, we found increased odds of COPD across all levels of fiber when omega-6 intake
was low and when omega-6:3 ratio is low, and lower odds with high omega-6 and omega-6:3
intake. We hypothesized that lower fiber and higher omega-6 intake would be associated with

higher odds of COPD, but these results suggest otherwise. The protective effect of fiber is seen
with high omega-6 consumption, but the odds of COPD are increased with low omega-6
consumption across all levels of fiber. The same trends are found with omega-6:3. To our
knowledge, this is the first study to show these interactions with COPD.
Our calculation for total omega-3 intake included ALA, which generally has a very poor
conversion rate to other compounds that function to resolve inflammation, namely EPA and
DHA. Because of this poor conversion, much of the ALA consumed is not biologically available
for other functions besides being an energy source and may not provide the same health benefits
DHA and EPA have been shown to provide.29 Since ALA comprises most of the total omega-3
Americans consume, our analysis could be affected by the inclusion of ALA in the total omega3, and should be considered when discussing the results.
When this interaction is considered, it opposes our hypothesis about the individual impact
of omega-6 intake and highlights the complexity these dietary variables have on their own and as
they work together in the body. In the body, omega-3 and omega-6 compete for enzymes during
metabolism. This can impact gene expression and the type and level of inflammation that
occurs, ultimately impacting outcomes in our study.25 Since our research indicates that the
effectiveness of fiber depends on the level of omega-6, omega-6 could possess some antiinflammatory properties at high levels in the body. It could also have an additive effect when
paired with increasing fiber levels. Research examining individual omega-3 and omega-6 intake
have not accounted for other dietary variables, so additional data examining this omega-fiber
interaction is very limited.
One considerable limitation of the study was the use of diet variables. To quantify
intake, we used the NHANES 24-hour dietary interview (What We Eat in America). It consists

of two separate interviews and relies on accurate recall from the participant about what and when
they ate. Although this method is valid, it is worth noting that self-reporting can be imprecise
and recall error can occur. Also, these interviews give a good idea of short-term consumption,
but they can lack accuracy about actual daily consumption habits.
In addition, the complexity of nutrient metabolism makes it difficult to determine exactly
how the body is processing these nutrients without considering the differing metabolism of each
participant. These nutrients have many different functions, and without measuring any
biomarkers, it’s difficult to determine how they are impacting the body. To overcome this,
including a serum biomarker in this analysis would allow measurement of inflammatory changes
and draw more definite conclusions about the impact of our dietary variables. Also, people who
consume appropriate levels of nutrients highlighted in this study likely perform other healthy
habits in their daily life. We tried to control for this by adjusting our models for important
lifestyle factors such as age, race, BMI, smoking status, education level, and poverty level.
The use of the NHANES population is a strength of our study. This is a large, nationally
representative sample, and our results are generalizable to the adult U.S. population. Also, using
diet variables presents a look at a modifiable risk factor that people can make practical changes
to in their life to improve health. By adding to the growing body of literature supporting the
association between dietary fiber and omega-3 intake and COPD outcomes and expanding
education programs about dietary influences, we can provide an alternative method of improving
health.
Future research regarding this topic would benefit from a deeper dive into the dietary
aspect of the study, including strict consideration of how total omega-3 and omega-6 intake is
quantified. By looking into the detail of the mechanisms of action of omega-3, omega-6, and

fiber in COPD patients, it would allow us to understand in more detail how these nutrients are
affecting the outcomes. Including a serum inflammation biomarker in the analysis would be a
good addition to advance this investigation and further explain initial findings.
As a whole, this study provides evidence for the support of the anti-inflammatory effects
of high fiber intake to lower odds of COPD and a number of respiratory morbidities in the U.S.
adult population. Our study also provides promising evidence about the functions of omega-3
and omega-6 with COPD and lung function, as well as a new look at the interaction between
fiber and omega-3 and omega-6 with COPD. To determine the effects of omega-3 and omega-6
intake on these outcomes and gain better insight on the interactions, further investigation is
necessary.

FIGURE 1. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) flow
diagram.

Variable
Age, years

Overall
55.70 (0.19)

COPD+
60.16(0.42)

COPD54.71(0.22)

p-value
<0.0001

Age, years

40-49
50-59
60-69
70-79

1975 (33.2)
1832 (32.1)
1878 (22.0)
1253 (12.7)

200 (19.2)
272 (28.2)
427 (31.1)
385 (21.6)

1775 (36.2)
1560 (33.0)
1451 (20.0)
868 (10.8)

<0.0001

Sex

Male
Female

3412 (47.9)
3526 (52.1)

834 (60.6)
450 (39.4)

2578 (45.1)
3076 (54.9)

<0.0001

29.17 (0.13)

27.86 (0.18)

29.46 (0.15)

<0.0001

BMI, kg/m2
BMI, kg/m2

Underweight: <18.5
Normal: 18.5-24.9
Overweight: 25.0-29.9
Obesity I:30.0-34.9
Obesity II: 35.0-39.9
Extremely Obese: 40+

86 (1.2)
1581 (24.9)
2466 (36.2)
1633 (22.1)
699 (9.4)
473 (6.2)

38(2.6)
376 (31.4)
445 (35.9)
270 (19.5)
98 (6.7)
57 (3.9)

48 (0.91)
1205 (23.4)
2021 (36.2)
1363 (22.7)
601 (10.0)
416 (6.7)

<0.0001

Race

Non-Hispanic White
Non-Hispanic Black
Mexican American/ Other
Hispanic
Other race, including multiracial

3270 (75.4)
1538 (9.9)
1686 (9.6)

780 (82.2)
258 (7.9)
197 (5.2)

2490 (73.9)
1280 (10.4)
1489 (10.6)

<0.0001

444 (5.0)

49 (4.7)

395 (5.1)

3.30 (0.05)

3.00 (0.09)

3.37 (0.06)

<0.0001

Poverty Ratio
Education

< High School
≥ High School and Some College
≥ College

1874 (16.8)
3447 (51.9)
1613 (31.3)

413 (22.7)
690 (59.2)
181 (18.0)

1461 (15.5)
2757 (50.2)
1432 (34.3)

<0.0001

Smoking Status

Never
Former
Current

3523 (51.8)
2091 (30.2)
1324 (18.0)

0 (0)
735 (57.2)
549 (42.8)

3523 (51.8)
1356 (24.2)
775 (12.5)

<0.0001

TABLE 1. Study population demographic characteristics stratified by COPD status.
Results are displayed as mean  standard error of the mean for continuous variables and as n (%) for categorical variables.
PROC SURVEYMEANS and PROC SURVEYFREQ were used for this analysis.
Definitions: COPD= prebronchodilator FEV1/FVC ratio < 0.7, no asthma diagnosis, and smoked 100 or more cigarettes in
their lifetime; BMI= body mass index; FEV1= forced expiratory volume in one second; FVC= forced vital capacity;
poverty ratio= a ratio of family income to poverty levels commonly used to establish eligibility for U.S. food assistance
programs.

Variable
Wheeze in past year

No
Yes

Overall
6175 (89.6)
760 (10.4)

COPD+
1019 (79.6)
265 (20.4)

COPD5156 (91.8)
495 (8.2)

p-value
<0.0001

Chronic Phlegm

No
Yes

6374 (92.5)
561 (7.5)

1065 (82.1)
219 (17.9)

5309 (94.8)
342 (5.2)

<0.0001

Chronic Cough

No
Yes

6273 (90.4)
659 (9.6)

1030 (79.5)
254 (20.5)

5243 (92.8)
405 (7.2)

<0.0001

Chronic Bronchitis

No
Yes

6573 (95.0)
365 (5.0)

1115 (86.3)
169 (13.7)

5458 (96.9)
196 (3.1)

<0.0001

FEV1/FVC

0.759 (0.002)

0.631 (0.003)

0.779 (0.001)

<0.0001

% Predicted FEV1

95.55 (0.37)

80.18 (0.93)

98.02 (0.29)

<0.0001

% Predicted FVC

98.13 (0.28)

96.78 (0.81)

98.35 (0.27)

<0.0001

TABLE 2. Study population clinical characteristics stratified by COPD status.
Data are reported as mean  standard error of the mean. PROC SURVEYMEANS was used for this analysis.
Definitions: Current wheeze= “yes” to the question “In the past 12 months, have you had wheezing or
whistling in your chest?”; Chronic Cough= a positive answer to the question “Do you usually cough on
most days for three consecutive months or more during the year?”; Chronic Phlegm= “yes” to the
question “Do you bring up phlegm on most days for 3 consecutive months or more during the year?”;
Chronic Bronchitis= both chronic cough and phlegm.

Variable
Fiber
(g/day)
Fiber
Quartiles

Overall
17.83 (0.22)

COPD+
16.84 (0.47)

COPD17.97 (0.24)

p-value
<0.0001

Q1, <11.6 g/d

1822 (24.5)

261 (32.0)

1561 (23.9)

0.0041

Q2, 11.6-16.1g/d
Q3, 16.1-22.5g/d
Q4, >22.5g/d

1610 (25.4)
1520 (24.6)
1475 (25.1)

169 (22.9)
172 (20.1)
175 (24.9)

1441 (25.8)
1348 (25.2)
1300 (25.1)

1.82 (0.02)

1.90 (0.06)

1.81 (0.02)

<0.0001

Q1, <1.1 g/d

1824 (25.0)

200 (23.9)

1624 (25.1)

0.37

Q2, 1.1-1.6g/d
Q3, 1.6-2.3g/d
Q4, >2.3g/d

1682 (25.0)
1518 (25.0)
1403 (25.0)

205 (23.3)
177 (24.2)
195 (28.6)

1477 (25.3)
1341 (25.1)
1403 (24.5)

16.42 (0.16)

17.25 (0.54)

16.30 (0.18)

<0.0001

Q1, <10.2g/d

1916 (25.0)

217 (26.0)

1699 (24.9)

0.23

Q2, 10.2-14.7g/d
Q3, 14.7-20.7g/d
Q4, >20.7g/d

1644 (25.0)
1511 (25.0)
1356 (25.0)

196 (21.9)
183 (23.9)
181 (28.3)

1448 (25.5)
1328 (25.2)
1175 (24.5)

9.69 (0.07)

9.66 (0.19)

9.70 (0.07)

<0.0001

Q1, <7.6

1732 (25.0)

210 (26.3)

1522 (24.8)

0.81

Q2, 7.6-9.1
Q3, 9.1-11.0
Q4, >11.0

1609 (25.0)
1574 (25.0)
1512 (25.0)

211 (26.0)
180 (24.3)
176 (23.5)

1398 (24.9)
1394 (25.1)
1512 (25.3)

Omega 3
(g/day)
Omega 3
Quartiles

Omega 6
(g/day)
Omega 6
Quartiles

Omega
6:3
Omega
6:3
Quartiles

TABLE 3. Dietary intake of fiber and omega -3 and 6- fatty acids stratified by COPD status.
Data are reported as mean  standard error of the mean. PROC SURVEYMEANS was used for this analysis.

Quartile of Dietary Fiber Intake
Variable
COPD +/COPD
GOLD
Wheeze
cough
phlegm
bronchitis

Q1
<11.6 g/d

Q2
11.6-16.1 g/d

Q3
16.1-22.5 g/d

Q4
>22.5 g/d

overall
p-value

Q1 vs Q4
p-value

P-trend

1.3(0.9-1.7)
0.8(0.5-1.1)

1.0(0.7-1.5)
0.8(0.5-1.3)

0.8(0.6-1.1)
0.8(0.6-1.1)

1
1

0.0381
0.33

0.0100
0.34

0.08
0.72

0.8(0.5-1.1)
0.6(0.4-0.8)
0.7(0.4-1.0)
0.6(0.4-1.0)

0.7(0.5-1.1)
0.8(0.5-1.1)
0.8(0.5-1.3)
0.9(0.6-1.5)

0.8(0.6-1.1)
0.9(0.7-1.3)
0.9(0.6-1.4)
1.1(0.7-1.8)

1
1
1
1

0.39
0.0109
0.08
0.0392

0.39
0.0012
0.0117
0.0054

0.0323
0.0031
0.06
0.0437

Quartile of Dietary Omega-3 Intake
Variable
COPD +/COPD
GOLD
wheeze
cough
phlegm
bronchitis

Q1, <1.1
g/d

Q2, 1.11.6g/d

Q3, 1.62.3g/d

Q4,
>2.3g/d

overall p-value

Q1 vs Q4
p-value

P Trend

1.0(0.7-1.4)
0.8(0.6-1.2)

0.8(0.6-1.1)
0.8(0.5-1.1)

0.8(0.6-1.2)
0.9(0.6-1.3)

1
1

0.33
0.55

0.44
0.61

0.57
0.23

0.9(0.6-1.3)
1.1(0.8-1.5)
0.9(0.6-1.4)
0.9(0.6-1.6)

0.8(0.6-1.2)
1.0(0.7-1.3)
1.0(0.7-1.6)
1.0(0.7-1.6)

1.0(0.7-1.4)
1.2(0.9-1.5)
1.0(0.7-1.4)
1.0(0.6-1.7)

1
1
1
1

0.69
0.49
0.90
0.97

0.61
0.61
0.57
0.69

0.90
0.75
0.99
0.97

Quartile of Dietary Omega-6 Intake
Variable

COPD +/COPD
GOLD
wheeze
cough
phlegm
bronchitis

Q1,
<10.2g/d

Q2, 10.214.7g/d

Q3, 14.7-20.7g/d

Q4, >20.7g/d

overall p-value

Q1 vs Q4
p-value

P
Trend

1
1

0.8(0.6-1.0)
1.0(0.7-1.4)

0.9(0.7-1.1)
1.0(0.7-1.4)

0.9(0.6-1.3)
1.2(0.7-1.9)

0.34
0.76

0.90
0.39

0.50
0.20

1
1
1
1

0.9(0.7-1.2)
1.0(0.7-1.4)
0.8(0.6-1.2)
1.0(0.6-1.5)

1.0(0.7-1.4)
1.2(0.8-1.7)
1.2(0.8-2.0)
1.3(0.8-2.1)

0.9(0.6-1.4)
0.9(0.6-1.4)
1.0(0.6-1.7)
1.0(0.6-2.0)

0.90
0.50
0.15
0.52

0.70
0.33
0.86
0.90

0.88
0.53
0.88
0.93

Quartile of Dietary Omega-6:3 Intake
Variable

Q1, <7.6

Q2, 7.6-9.1

Q3, 9.1-11.0

Q4, >11.0

overall p-value

Q1 vs Q4 p-value

P Trend

COPD +/COPD
GOLD
wheeze
cough
phlegm
bronchitis

1
1

1.0(0.7-1.4)
0.9(0.6-1.2)

0.9(0.6-1.2)
0.8(0.6-1.2)

0.9(0.6-1.2)
0.9(0.6-1.4)

0.67
0.78

0.41
0.79

0.96
0.60

1
1
1
1

1.1(0.8-1.5)
0.7(0.5-1.0)
0.9(0.6-1.2)
0.7(0.4-1.2)

1.1(0.8-1.5)
1.1(0.8-1.6)
1.0(0.7-1.6)
1.0(0.6-1.6)

0.9(0.7-1.3)
0.8(0.6-1.1)
1.0(0.7-1.5)
1.0(0.7-1.5)

0.59
0.0146
0.74
0.39

0.30
0.42
0.61
0.44

0.15
0.39
0.69
0.61

TABLE 4. Relationship of respiratory outcomes with dietary quartiles.
Data are reported as odds ratios with 95% confidence intervals. PROC SURVEYLOGISTIC was used for this
analysis. It was adjusted for age category, BMI (underweight <18.5, normal 18.5-24.9, and overweight/obese 25+),
poverty ratio category (≤1.9, 2-4.9, 5+), sex, race, mean energy intake, and smoking status. For fiber and omega 3,
Q4 was used as the reference category and valued at 1. For omega 6 and omega 6:3, Q1 was used as the reference
category and valued at 1.

FIBER
Variable
FEV1/FVC ratio
FEV1 (%
Predicted)
FVC (%
Predicted)

OMEGA 3
ß-coefficient
-0.0013
0.975

p-value
0.22
0.0001

1.108

<0.0001

ß-coefficient
-0.0000094
-0.1409

p-value
0.99
0.64

-0.1136

0.63

OMEGA 6
Variable
FEV1/FVC ratio
FEV1 (%
Predicted)
FVC (%
Predicted)

Variable
FEV1/FVC ratio
FEV1 (%
Predicted)
FVC (%
Predicted)

ß-coefficient
-0.00013
-0.067

p-value
0.91
0.84

-0.089

0.79

OMEGA 6:3
Variable
FEV1/FVC ratio
FEV1 (%
Predicted)
FVC (%
Predicted)

ß-coefficient
0.000845
-0.0249

p-value
0.48
0.93

-0.121

0.65

TABLE 5. Relationship of lung function and dietary omega -3 and -6 fatty acids.
Data are reported as regression coefficients with associated p-values. PROC SURVEYLOGISTIC was used for this
analysis. It was adjusted for age (40-49 years, 50-59 years, 50-69 years, 70-79 years), BMI (<18.5, 18.5-24.9, ≥25),
poverty ratio category (≤1.9, 2-4.9, ≥5), sex, race, mean energy intake, and smoking status.

Quartile of Dietary Fiber Intake
Variable
Omega-6
High
Low
Omega 6:3
High
Low
Omega 3
High
Low

Interaction p-value

Q1,
<10.2g/d

Q2
10.2-14.7g/d

Q3
14.7-20.7g/d

Q4
>20.7g/d

0.8 (0.4,1.3)
2.2 (1.5,3.3)

0.7 (0.5,1.2)
1.8 (1.1,2.9)

0.7 (0.5,1.0)
1.3 (0.8,2.1)

1
1

0.8 (0.5,1.3)
1.8 (1.2,2.7)

0.6 (0.3,0.9)
1.8 (1.1,2.9)

0.5 (0.4,0.8)
1.2 (0.8,1.7)

1
1

1.2 (0.7,2.0)
1.5 (0.9,2.3)

1.0 (0.7,1.5)
1.2 (0.7,2.0)

0.8 (0.5,1.1)
1.0 (0.6,1.7)

1
1

0.0269

0.0142

0.84

TABLE 6. Interaction of omega -3, -6, -6:3 and fiber for COPD status (yes/no).
Data are reported as odds ratios with 95% confidence intervals. PROC SURVEYLOGISTIC was used
for this analysis and adjusted for age (40-49 years, 50-59 years, 50-69 years, 70-79 years), BMI, kg/m2
(<18.5, 18.5-24.9, >25), poverty ratio category (≤1.9, 2-4.9, ≥ 5), sex, race, mean energy intake, and
smoking status. For fiber, Q4 was used as the reference category and valued at 1.
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